Search Result

Isoforms Recommended:	CDK5

Results for "

Cdk5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Amyloid-β (1) Apoptosis (12) Aurora Kinase (1) Autophagy (3) Casein Kinase (1) CDK (67) CFTR (1) DNA/RNA Synthesis (1) DYRK (1) ERK (1) GSK-3 (21) HSV (2) JAK (2) JNK (1) Ligands for Target Protein for PROTAC (1) Lipoxygenase (1) MEK (2) Molecular Glues (2) mTOR (1) Parasite (3) PKC (1) PPAR (5) PROTACs (1) Proton Pump (2) Small Interfering RNA (siRNA) (8)
By Research Areas:	Cancer (50) Infection (3) Inflammation/Immunology (2) Metabolic Disease (10) Neurological Disease (15)
Oligonucleotides:	Nucleosides and their Analogs (1) Pre-designed siRNA Sets (8) siRNAs (8)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-123772

CDK5 inhibitor 20-223 CP668863	CDK	Cancer
CDK5 inhibitor 20-223 is a potent *CDK2* and *CDK5* inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .

HY-P10440

Cdk5i peptide	CDK	Neurological Disease
Cdk5i peptide is a 12-amino acid peptide fragment derived from Cdk5. Cdk5i peptide is an inhibitor of *Cdk5* peptide. Cdk5i peptide can be used in the stud y of neurodegenerative diseases .

HY-139725

CDK5-IN-1	CDK	Metabolic Disease
CDK5-IN-1, a potent *CDK5* inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research .

HY-145694

CDK5-IN-3	CDK	Metabolic Disease
CDK5-IN-3 (compound 11) is a potent and selective *CDK5* inhibitor, with IC₅₀s of 0.6 nM and 18 nM for *CDK5/p25* and *CDK2/CycA, respectively. CDK5*-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .

HY-RS02384

CDK5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
CDK5 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK5 Human Pre-designed siRNA Set A CDK5 Human Pre-designed siRNA Set A

HY-RS02385

Cdk5 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk5 Mouse Pre-designed siRNA Set A Cdk5 Mouse Pre-designed siRNA Set A

HY-RS02386

Cdk5 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk5 Rat Pre-designed siRNA Set A Cdk5 Rat Pre-designed siRNA Set A

HY-145693

CDK5-IN-2	CDK	Others
CDK5-IN-2 (compound 15) is a highly selective *CDK5* inhibitor with IC₅₀s of 0.2 and 23 for CDK5/p25 and CDK2/CycA, respectively .

HY-161595

CDK5-IN-4	CDK GSK-3	Cancer
CDK5-IN-4 (compound 4) is a potent multikinase type-II inhibitor targeting CDK5, with an IC₅₀ of 9.8 μM. CDK5-IN-4 also inhibits GSK-3α, GSK-3β, CDK9, and CDK2, with IC₅₀ values of 0.98, 4.00, 1.76, and 6.24 μM, respectively. CDK5-IN-4 can be used for glioblastoma research .

HY-RS02387

CDK5R1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK5R1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5R1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK5R1 Human Pre-designed siRNA Set A CDK5R1 Human Pre-designed siRNA Set A

HY-RS02388

CDK5R2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK5R2 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5R2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK5R2 Human Pre-designed siRNA Set A CDK5R2 Human Pre-designed siRNA Set A

HY-RS02389

CDK5RAP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK5RAP1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5RAP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK5RAP1 Human Pre-designed siRNA Set A CDK5RAP1 Human Pre-designed siRNA Set A

HY-RS02390

CDK5RAP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK5RAP2 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5RAP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK5RAP2 Human Pre-designed siRNA Set A CDK5RAP2 Human Pre-designed siRNA Set A

HY-RS02391

CDK5RAP3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK5RAP3 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5RAP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK5RAP3 Human Pre-designed siRNA Set A CDK5RAP3 Human Pre-designed siRNA Set A

HY-134622

*GSK-3/CDK5/CDK2-IN-1*	CDK GSK-3	Neurological Disease Cancer
GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of *cdk5, cdk2, and GSK-3* extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases .

HY-P1906

*[pThr3]-CDK5* Substrate**	CDK	Neurological Disease
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM .

HY-P1906A

*[pThr3]-CDK5* Substrate TFA**	CDK	Neurological Disease
[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM .

HY-120542

SR 1824	PPAR	Metabolic Disease
SR 1824 is a non-agonist PPARγ ligand that blocks Cdk5-mediated phosphorylation. SR 1824 has anti-diabetic effects .

HY-N12625A

(S)-(-)-O-Demethylbuchenavianine	CDK	Cancer
(S)-(-)-O-Demethylbuchenavianine (Compound (S)-(−)-1) is a flavonoidal alkaloids. (S)-(-)-O-Demethylbuchenavianine is a potent *CDK* inhibitor, with IC₅₀ values of 0.03 and 0.05 μM for CDK1 and CDK5, respectively .

HY-147387

DSS30	CDK Amyloid-β	Inflammation/Immunology
DSS30 is a *P25/CDK5* inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloid precursor protein lyase 1 (BACEl) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .

HY-108348

BML-259	CDK	Neurological Disease
BML-259 is a potent cyclin-dependent kinase 5 *(Cdk5)* inhibitor, with IC₅₀s of 64 and 98 nM for Cdk5 and Cdk2, respectively .

HY-112468

PNU112455A hydrochloride	CDK	Cancer
PNU112455A hydrochloride is an ATP-competitive *CDK2* and *CDK5* inhibitor. PNU112455A hydrochloride binds to the ATP site of CDK2 and CDK5 with K_ms of 3.6 and 3.2 μM, respectively .

HY-144117

GFB-12811	CDK	Metabolic Disease
GFB-12811 is a high selective and orally active *CDK5* inhibitor with an IC₅₀ of 2.3 nM. GFB-12811 is highly selective over the other tested kinases (CDK1/2/6/7/9) .

HY-112382

Iso-Olomoucine	Others	Others
Iso-olomoucine is an inactive stereoisomer of the CDK5 inhibitor olomoucine with IC₅₀ >1 mM .

HY-103381

NSC693868	CDK GSK-3	Cancer
NSC693868 is a selective inhibitor of *CDK1* and *CDK5* with IC₅₀s of 600 nM and 400 nM, respectively. NSC693868 less potently inhibits GSK3β with an IC₅₀ of 1 µM) and does not block CDC25 activity. NSC693868 is used to help define the roles of CDK1 and CDK5 in various signaling pathways .

HY-12483

SR1664	PPAR	Metabolic Disease
SR1664 is a PPARγ antagonist. SR1664 binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC₅₀=80 nM; K_i= 28.67 nM) .

HY-10492

Dinaciclib Maximum Cited Publications 46 Publications Verification SCH 727965	CDK Apoptosis	Cancer
Dinaciclib (SCH 727965) is a potent inhibitor of *CDK, with IC₅₀s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9*, respectively .

HY-15241

NVP-LCQ195 LCQ-195; AT9311	CDK	Cancer
NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.

HY-18299

Purvalanol B 1 Publications Verification NG 95	CDK Parasite	Infection Cancer
Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor *CDK, with IC₅₀s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK* over a range of other protein kinases (IC₅₀>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum .

HY-30237

(R)-Roscovitine 30+ Cited Publications Seliciclib; CYC202	CDK	Cancer
(R)-Roscovitine (Seliciclib) is an orally bioavailable and selective *CDKs* inhibitor with IC₅₀s of 0.2 μM, 0.65 μM, and 0.7 μM for *CDK5, Cdc2, and CDK2*, respectively.

HY-112336

Aloisine RP106	CDK GSK-3	Neurological Disease
Aloisine RP106 (compound 38) is a potent inhibitor of Cdk1/cyclin B, *Cdk5/p25, and GSK3* with IC₅₀s of 0.70µM, 1.5µM, 0.92 µM, respectively .

HY-162670

Anticancer agent 238	CDK	Cancer
Anticancer agent 238 (compound 5) is an anticancer agent with a notably strong binding affinity towards the CDK-5 enzyme. Anticancer agent 238 shows a strong efficacy agains HCT116 and MCF7 cells, with IC₅₀ values of 13.46 µM and 16.43 µM, respectively .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, *CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-111931

Indirubin-3'-monoxime-5-sulphonic acid	CDK GSK-3	Cancer
Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of *CDK1, CDK5, and GSK-3β* with IC₅₀s of 5 nM, 7 nM, and 80 nM, respectively .

HY-111930

5-Iodo-indirubin-3'-monoxime	GSK-3 CDK	Cancer
5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, *CDK5/P25* and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC₅₀s of 9, 20 and 25 nM, respectively .

HY-108359

Alsterpaullone 1 Publications Verification 9-Nitropaullone; NSC 705701	CDK GSK-3 Apoptosis	Cancer
Alsterpaullone (9-Nitropaullone) is a potent *CDK* inhibitor, with IC₅₀s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and *CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC₅₀s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis* in leukemia cell line .

HY-18299A

Purvalanol A 2 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent *CDK* inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-111254

GQ-16	PPAR	Metabolic Disease
GQ-16 is a moderate affinity ligand for the ligand-binding domain (LBD) of PPARγ, exhibiting a K_i of 160 nM. GQ-16 is an effective inhibitor of Cdk5-mediated phosphorylation of PPARγ. GQ-16 is a partial agonist of PPARγ with reduced adipogenic actions. GQ-16 promotes insulin Sensitization without weight gain .

HY-147705

PPARγ phosphorylation inhibitor 1	PPAR	Metabolic Disease
PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent PPARγ binder with the IC₅₀ of 24 nM. PPARγ phosphorylation inhibitor 1 inhibits CDK5-mediated phosphorylation of PPARγ Ser273 with the IC₅₀ of 160 nM. PPARγ phosphorylation inhibitor 1 displays negligible PPARγ agonism in a reporter gene assay. Antidiabetic effects .

HY-103383

(R)-DRF053 dihydrochloride	CDK Casein Kinase	Neurological Disease Cancer
(R)-DRF053 dihydrochloride is a potent casein kinases 1 (CK1), CDK1/cyclin B and *CDK5/p25* inhibitor with IC₅₀s of 14 nM, 220 nM and 80 nM, respectively. (R)-DRF053 dihydrochloride prevents the CK1-dependent production of amyloid-beta in a cell model .

HY-10012

AZD-5438 10+ Cited Publications	CDK	Cancer
AZD-5438 is a potent *CDK1, CDK2, and CDK9* inhibitor, with IC₅₀s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .

HY-123279

OM137	Aurora Kinase CDK	Cancer
OM137 is an aurora kinase inhibitor, with an IC₅₀ of 21.7 μM (Aurora A kinase) and 2.4 μM (Aurora B kinase). OM137 also inhibits Cdk1/cyclinB and Cdk5/p25 with an approximate IC₅₀ of 20 μM. OM137 reduces spindle checkpoint-signaling proteins (Mad2 and BubR1) at the kinetochores of chromosomes .

HY-121035

7BIO 7-Bromoindirubin-3-Oxime	CDK GSK-3	Neurological Disease
7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice ^[1].

HY-10580

GSK 3 Inhibitor IX 10+ Cited Publications 6-Bromoindirubin-3'-oxime; BIO; MLS 2052	GSK-3 CDK Apoptosis	Cancer
GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and *CDK1-cyclinB* complex with IC₅₀s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.

HY-19807

Indirubin-3'-monoxime 3 Publications Verification Indirubin-3'-oxime	GSK-3 CDK Lipoxygenase	Cancer
Indirubin-3'-monoxime is a potent GSK-3β inhibitor, and weakly inhibits *5-Lipoxygenase, with IC₅₀s of 22 nM and 7.8-10 µM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC₅₀*s of 100 and 180 nM.

HY-117025A

Manzamine A hydrochloride 1 Publications Verification Keramamine A hydrochloride	GSK-3 CDK Parasite Proton Pump HSV Autophagy	Infection Neurological Disease Cancer
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and *CDK-5* with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1 .

HY-117025

Manzamine A Keramamine A	GSK-3 CDK Parasite Proton Pump HSV Autophagy	Infection Neurological Disease Cancer
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and *CDK-5* with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1 .

HY-114903

(E/Z)-BIO-acetoxime GSK-3 Inhibitor X	GSK-3 CDK	Neurological Disease Metabolic Disease Cancer
(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective GSK-3α/β inhibitor, with an IC₅₀ of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over *CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC₅₀*=2.4, 4.3, 63 μM) .

HY-161926

YGT-31	PPAR	Metabolic Disease
YGT-31 is a modulator for PPARγ with an IC₅₀ of 1.72 μM, and a K_i of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .

HY-150082

CP681301	CDK DNA/RNA Synthesis	Cancer
CP681301 is a potent *CDK5* inhibitor. CP681301 shows antiproliferative activity. CP681301 decreases the expression of CD133, OLIG2, SOX2, KI67, pCDK5 protein level in GSCs (Glioma stem cells). CP681301 reduces self-renewal in mouse glioma xenografts. CP681301 shows anti-tumor activity in Drosophila .

Cat. No.	Product Name	Target	Research Area

HY-P2668

Cdk5 Substrate	Peptides	Others
Cdk5 Substrate is a biological active peptide. (substrate for the cdc2 protein kinase)

HY-P10440

Cdk5i peptide	CDK	Neurological Disease
Cdk5i peptide is a 12-amino acid peptide fragment derived from Cdk5. Cdk5i peptide is an inhibitor of *Cdk5* peptide. Cdk5i peptide can be used in the stud y of neurodegenerative diseases .

HY-P1906

*[pThr3]-CDK5* Substrate**	CDK	Neurological Disease
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM .

HY-P1906A

*[pThr3]-CDK5* Substrate TFA**	CDK	Neurological Disease
[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM .

Recombinant Proteins Recommended:

Cyclin-Dependent Kinase 5 (CDK5)

Species:	Human (3)
Tag:	His (3) GST (2) Flag (2)
Source:	P. pastoris (1) Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P72298

	CDK5 Protein, Human (P.pastoris, His) Cdk5; Cell division protein kinase 5; Protein kinase Cdk5 splicing; PSSALRE	Human	P. pastoris
	CDK5 is a proline-directed serine/threonine protein kinase that critically regulates neuronal cell cycle, differentiation and potential apoptosis in neuronal diseases by preventing cell cycle re-entry. It interacts with numerous proteins involved in neuronal development and coordinates processes such as survival, migration, differentiation, axonal growth, synaptogenesis, and neurotransmission. CDK5 Protein, Human (P.pastoris, His) is the recombinant human-derived CDK5 protein, expressed by P. pastoris , with N-His labeled tag. The total length of CDK5 Protein, Human (P.pastoris, His) is 292 a.a., with molecular weight of ~38.0 kDa.

HY-P702685

	CDK5-p25 Protein, Human (sf9, GST, His, Flag) Cdk5; cyclin-dependent kinase 5; PSSALRE; TPKII catalytic subunit; protein kinase Cdk5 splicing; cell division protein kinase 5; serine/threonine-protein kinase PSSALRE; tau protein kinase II catalytic subunit	Human	Sf9 insect cells
	CDK5 is a proline-directed serine/threonine protein kinase that critically regulates neuronal cell cycle, differentiation and potential apoptosis in neuronal diseases by preventing cell cycle re-entry. It interacts with numerous proteins involved in neuronal development and coordinates processes such as survival, migration, differentiation, axonal growth, synaptogenesis, and neurotransmission. CDK5-p25 Protein, Human (sf9, GST, His, Flag) is the recombinant human-derived CDK5-p25, expressed by Sf9 insect cells , with N-GST, N-His, N-Flag labeled tag. ,

HY-P702686

	CDK5-p35 Protein, Human (sf9, GST, His, Flag) Cdk5; cyclin-dependent kinase 5; PSSALRE; TPKII catalytic subunit; protein kinase Cdk5 splicing; cell division protein kinase 5; serine/threonine-protein kinase PSSALRE; tau protein kinase II catalytic subunit	Human	Sf9 insect cells
	CDK5 is a proline-directed serine/threonine protein kinase that critically regulates neuronal cell cycle, differentiation and potential apoptosis in neuronal diseases by preventing cell cycle re-entry. It interacts with numerous proteins involved in neuronal development and coordinates processes such as survival, migration, differentiation, axonal growth, synaptogenesis, and neurotransmission. CDK5-p35 Protein, Human (sf9, GST, His, Flag) is the recombinant human-derived CDK5-p35, expressed by Sf9 insect cells , with N-His, N-GST, N-Flag labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80078

	Cdk5 Antibody	WB, IHC-P, FC, IP	Human, Mouse, Rat
	Cdk5 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 33 kDa, targeting to Cdk5. It can be used for WB,IHC-P,FC,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80613

	CDK5 Antibody (YA796) Cdk 5; Cdk5; Cdk5_HUMAN; Cell division protein kinase 5; Crk6; Cyclin dependent kinase 5; Cyclin-dependent kinase 5; Protein kinase Cdk5 splicing; PSSALRE; Serine threonine protein kinase PSSALRE; Serine/threonine-protein kinase PSSALRE; Tau protein kinas	WB, ICC/IF	Human, Mouse, Rat, Monkey
	CDK5 Antibody (YA796) is a non-conjugated and Mouse origined monoclonal antibody about 33 kDa, targeting to CDK5 (2E8). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat, Monkey.

HY-P82183

	CDK5RAP3 Antibody (YA1928) C53; IC53; LZAP; HSF-27; MST016; PP1553; OK/SW-cl.114	WB, IHC-P, IP	Human, Mouse
	CDK5RAP3 Antibody (YA1928) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1928), targeting CDK5RAP3, with a predicted molecular weight of 57 kDa (observed band size: 70 kDa). CDK5RAP3 Antibody (YA1928) can be used for WB, IHC-P, IP experiment in human, mouse background.